Vasculitis & polymyalgia rheumatica
Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study
Authors' conclusion
TMP-SMX was dispensed to a minority of RTX-treated GPA patients, more often to those on glucocorticoids and with recent hospitalization.
Study context
- Population
- Adults with granulomatosis with polyangiitis (GPA) treated with rituximab (RTX), Merative Marketscan Research Databases (2011–2020), USA; mean age 50.9, 54% female
- Participants
- 1,877 adults
- Outcome
- Frequency, persistence and factors associated with TMP-SMX prophylaxis (≥28-day prescription dispensed within a month of starting RTX)
Methodological detailsclaims database (Merative Marketscan, 2011-2020), multivariable logistic regression, Cox proportional hazards regression
- Claims database (Merative Marketscan, 2011-2020)
- Multivariable logistic regression
- Cox proportional hazards regression
Main finding
As reported in the abstract
Received trimethoprim-sulfamethoxazole (TMP-SMX) (n = 426)
23%
Median persistence of TMP-SMX, days (IQR 83-248)
141
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Factors associated with TMP-SMX prophylaxis (multivariable analyses)Prednisone ≥20 mg/day in month prior to RTXvs No prednisone | 3.96 (3.0–5.2) | |
| Factors associated with TMP-SMX prophylaxis (multivariable analyses)Prednisone 1-19 mg/day in month prior to RTXvs No prednisone | 2.63 (1.8–3.8) | |
| 0.20.5125Odds ratio (log scale) |
Factors associated with TMP-SMX prophylaxis (multivariable analyses)
| OR (95% CI) | ||
|---|---|---|
| MTX use in 6 months prior to RTX | 1.48 (1.04–2.1) | |
| Intensive care in 6 months prior to RTX | 1.95 (1.4–2.7) | |
| Non-intensive care hospitalization in 6 months prior to RTX | 1.56 (1.2–2.1) | |
| Female sexNegatively associated with TMP-SMX use | 0.63 (0.5–0.8) | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study. Arthritis Res Ther. Published 29 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →